Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Collateral Therapeutics (CLTX) -- Ignore unavailable to you. Want to Upgrade?

To: Silver Knife who wrote (9)	7/1/1999 12:26:00 AM
From: Jibacoa	Respond to of 35

SILVER: Why don't you ask Jill to add the daily price performance at the bottom of your thread? Bernard

To: Silver Knife who wrote (9)	7/1/1999 12:31:00 AM
From: Jibacoa	Respond to of 35

Silver: I guess the move on CLTX is probably related to the article in Circulation last week in relation to CHF.: SAN DIEGO, June 22 /PRNewswire/ -- Collateral Therapeutics (Nasdaq: CLTX) today announced hat a new preclinical study published in the current issue of Circulation found that the AC-6 gene may improve heart function in a preclinical animal model that closely resembles human congestive heart failure (CHF). Collateral exclusively licensed the technology used in this research from the University of California in 1997 and, following the filing of an IND, expects to begin clinical trials of CORGENIC(TM), an AC-6 gene therapy treatment for clinical CHF, early next year. Bernard

To: Silver Knife who wrote (9)	2/25/2000 8:43:00 PM
From: JMarcus	Read Replies (1) \| Respond to of 35

Silver, I don't suppose you are still long CLTX. This thread has been dead for nearly a year. From today's action, it looks like CLTX is starting to make its big move. I had worried about the impact of the Jessie Gelsinger debacle upon a company like CLTX that uses the adenovirus for a gene vector. I spoke to a company rep. at an Informed Investors Forum a month or so ago and it turns out that there is little reason for concern. First, the company's therapy for growing new heart blood vessels is a one-shot administration, so there is no issue about developing an immune response that might flare up in a follow-on administrations of the therapy. Second, the heart muscle is much less susceptible to an immune response than other organs are. Third, the uptake of the vector into heart and vascular tissue is proving to be very rapid and thorough, so there is no real issue about the adenoviruses spreading to other areas in the body. Bless my luck, I went long first thing this morning, before the big rise. Marc